EZH2 and Ewing sarcoma: A phase 2 clinical trial (NCT03213665) evaluated tazemetostat in pediatric patients with relapsed or refractory disease and found that EZH2 mutations were present in 3/20 (15%) tumors, 2/20 of which were identified in patients with ES [70].